Wire · regulatory
FDA gains 'continuity' as Mikhail, Davis named permanent CBER, CDER leaders
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The FDA has appointed permanent leaders for its CBER and CDER divisions, bringing stability after nearly two years of leadership turnover.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You must adjust to a steadier FDA leadership that may speed up regulatory decisions; product approvals could move faster with less leadership disruption.
◆ Coverage
2 sources · 9 Sep 2026
◆ Related on Wire
◆ Topics
Biotechfdaleadershipbiotech-regulationus-health-regulation